Clinical Trial: A Study to Evaluate Efficacy and Safety of HM11260C in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin and Dapagliflozin

U.S., Jan. 31 -- ClinicalTrials.gov registry received information related to the study (NCT07379333) titled 'A Study to Evaluate Efficacy and Safety of HM11260C in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin and Dapagliflozin' on Jan. 23.

Brief Summary: A multicenter, randomized, double-blind, phase 3 study to evaluate efficacy and safety of HM11260C in patients with type 2 diabetes mellitus inadequately controlled with metformin and dapagliflozin

Study Start Date: Feb., 2026

Study Type: INTERVENTIONAL

Condition: Type 2 Diabetes

Intervention: DRUG: HM11260C

Test drug

DRUG: Placebo

Placebo drug

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Hanmi Pharmaceutical Company Limited

Published by HT D...